Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Recent advances in diabetic gastroparesis
1. “
”
CURRENT AND
EMERGING MEDICAL
THERAPIES FOR
GASTROPARESIS
Short Topic
Dr Shinde Viraj Ashok
Junior Resident – 3
Department of Pharmacology
Current and emerging medical therapies for gastroparesis
1
Guided by
Dr Sonali Pimpalkhute
Associate Professor
Department of Pharmacology
3. INTRODUCTION
Gastroparesis - Constellation of disorders of
varying aetiology & pathophysiology
Gastroparesis –
Defined by objective evidence of delayed gastric
emptying in absence of obstruction
Symptoms commonly include early satiety, post-
prandial fullness, bloating, nausea, vomiting &
abdominal pain
Current and emerging medical therapies for gastroparesis
3
4. INTRODUCTION CONT’D
Mainstay of medical treatments includes
Modifying lifestyle & diet
Improving glucose control in diabetics
Prokinetic, anti-emetic & analgesic drugs
Non-medical modalities
Acupuncture
Hypnotherapy
Gastric electric stimulation & surgical procedures -
Reserved for rare & severely refractory patients
Current and emerging medical therapies for gastroparesis
4
6. TIGHTER GLUCOSE CONTROL IN
DIABETICS
Chronically elevated blood glucose level in diabetes
results in damage to vagus nerve & blood vessels of
stomach
In a Multicenter Safety, Feasibility & Potential
Efficacy of Continuous Glucose Monitoring & Insulin
Pump Therapy in Diabetic Gastroparesis (GLUMIT-
DG) study
Preliminary results – Continuous glucose monitoring
(CGM) & combined with insulin pump
Improves glycemic control
Associated with improved symptoms & gastric
emptying
Current and emerging medical therapies for gastroparesis
6
7. REVIEWING MEDICATIONS
Various drugs
Analgesic, Muscle relaxant, Antihistamines &
Neuropsychiatric medications like antidepressants -
may delay gastric emptying
↓ or withdrawn when possible
Diabetes medications - mimic or modify incretins can
further slow gastric emptying
Amylin & exenatide - inhibits gastric emptying &
should be avoided in gastroparesis
Inhibitors of enzyme dipeptidyl peptidase 4 (DPP-4) -
do not delay gastric emptying nor reduce food intake
& should be considered as replacements
Current and emerging medical therapies for gastroparesis
7
8. DIETARY CHANGES
Small frequent meal, low-fat, low-residue & ↑ liquid
content meals are best tolerated in patients with
symptomatic gastroparesis
Chewing food well, drinking non-carbonated liquids
with meals & avoiding lying down for 2 h after a
meal may assist with gastric emptying
Current and emerging medical therapies for gastroparesis
8
9. DIETARY CHANGES CONT’D
Ginger, peppermint & lavender, taken on their own,
appear helpful in ↓ discomfort & symptoms of
gastroparesis
Ginger (1.2 g) - accelerate gastric emptying & enhance
antral contractions over placebo but does not alter
plasma levels of gut peptide GLP-1, motilin or ghrelin
Peppermint tea
For some symptoms of gastroparesis - abdominal pain,
bloating & gas
Anti-spasmodic, anti-inflammatory, serotonergic & anti-
bacterial properties
Current and emerging medical therapies for gastroparesis
9
10. CURRENT MEDICAL
TREATMENTS
Medications used commonly for gastroparesis
include prokinetics, analgesics & anti-emetics.
Current and emerging medical therapies for gastroparesis
10
11. PROKINETICS
Dompamine D2-R antagonists
Metoclopramide & domperidone - equally effective in
↓ symptoms of diabetic gastroparesis
Metoclopramide
D2 receptor antagonist & 5-hydroxytryptamine
receptor 4 (5-HT4) agonist
Prokinetic action & anti-emetic properties
Provides prolonged symptomatic relief in
gastroparesis
US-FDA - approved for gastroparesis
Current and emerging medical therapies for gastroparesis
11
12. PROKINETICS CONT’D
Metoclopramide cont’d
Overall adverse central nervous system (CNS)
effects of metoclopramide, e.g., somnolence, dystonia
& reduction in mental acuity, can be severe
Tardive dyskinesia can be irreversible & disfiguring -
FDA black box warning in 2009
Treatment beyond 3 months should be avoided in
most cases.
Current and emerging medical therapies for gastroparesis
12
13. PROKINETICS CONT’D
Domperidone
Anti-emetic & prokinetic effects
Unlike metoclopramide, CNS reactions are uncommon
because of less penetration of blood–brain barrier
Rationally suitable for use in gastroparetic patients such as
with Parkinson’s disease
Treatment - doses of 80–120 mg per day for up to 3 months
is tried before considering as treatment failure
US - FDA issued warning about cardiac safety - regarding
QT prolongation
Intravenous dosage form - withdrawn due to cardiotoxicity
Current and emerging medical therapies for gastroparesis
13
14. PROKINETICS CONT’D
Itopride
Antiemetic & prokinetic properties
Has D2 antidopaminergic & anti-ChE (ACh potentiating)
activity, but very low affinity for 5-HT4 receptor
Very similar to domperidone & seems to be devoid of any
cardiac toxicity or CNS side effects
Levosulpiride
Dopamine D2 receptor antagonist
Reported to improve gastric emptying & symptoms (nausea,
vomiting & early satiety) in diabetic gastroparesis during 6
months of treatment
Current and emerging medical therapies for gastroparesis
14
15. SEROTONERGIC 5-HT4
AGONISTS
Cisapride
Mixed 5-HT4 agonist/5-HT3 antagonist
↑ acetylcholine release from enteric nervous
system & directly ↑ smooth muscle contractions –
↓ gastric emptying time
Withdrawn in 2000 - side effect of causing long
QT syndrome
Mosapride
Improves gastric emptying & symptoms of
gastroparesis & improves glycemic control
Current and emerging medical therapies for gastroparesis
15
16. SEROTONERGIC 5-HT4
AGONISTS CONT’D
Prucalopride
Dose selectivity for 5-HT4 receptors over cardiac
human ether-a-go-go-related gene (hERG) channel
& other receptors & has low adverse effects
Accelerates gastric emptying in animal models
Currently being studied for use in gastroparesis &
dyspepsia
Current and emerging medical therapies for gastroparesis
16
17. MOTILIN RECEPTOR AGONISTS
Erythromycin
Effect on gastroparesis - two pathways activating
motilin receptors on cholinergic neurons & muscle
Most effective intravenous prokinetic agent in
acute setting - initial management of hospitalized
patients with diabetic gastroparesis
Rapid development of tolerance is seen - By 4
weeks of oral treatment
Drawbacks - Potential to induce abdominal cramps,
nausea & vomiting & to slow small intestinal transit
Current and emerging medical therapies for gastroparesis
17
18. MOTILIN RECEPTOR AGONISTS
CONT’D
Clarithromycin & azithromycin
Promotilides & ↑ antral contractions
Effect on motilin receptor requires metabolism by
acid & this should be kept in mind while prescribing
to patients with dyspepsia , there by potentially
making drug less effective as a promotilide
Fewer drug interactions than erythromycin, less
incidence of QTc interval prolongation, a longer
half-life & fewer untoward GI effects
Current and emerging medical therapies for gastroparesis
18
20. ANTIEMETICS
Prochlorperazine
D2 antagonist - one of most commonly used medicines for
treatment of nausea in patients with gastroparesis
Major side effects are sedation, extrapyramidal side effects
Granisetron transdermal form - effective for refractory nausea
& vomiting in gastroparesis
Aprepitant
Substance P antagonist & works by blocking neurokinin 1 (NK1)
receptor
Effective for refractory nausea in severe gastroparesis & is
currently under investigation
Current and emerging medical therapies for gastroparesis
20
21. PAIN MANAGEMENT
Anti-convulsant/anti-epileptic drugs have much
less adverse effect on GI motility & could be very
valuable options for treating pain associated with
gastroparesis
Of alternative medical treatments, acupuncture &
acupressure (shiatsu) treatment may lead to
symptomatic improvement in patients with
gastroparesis
Current and emerging medical therapies for gastroparesis
21
22. GASTRIC ACID SUPPRESSION
Stomach acid suppression plays important role for
overall symptom management in gastroparesis
Careful choice of acid-suppressing drugs can
optimize gastroparesis symptom management
Nizatidine - Histamine H2 receptor antagonist -
demonstrated to hasten stomach emptying in
patients with Parkinson’s disease
Current and emerging medical therapies for gastroparesis
22
23. GASTRIC ACID SUPPRESSION
CONT’D
Misoprostol synthetic prostaglandin E1 analogue
Particularly at higher doses - Profound effect on
intestinal post-prandial motility & results in
accelerated transit time, particularly expediting
orocecal transit
Current and emerging medical therapies for gastroparesis
23
24. TARGETING ACCOMMODATION
Impaired accommodation - may contribute to
symptoms of post-prandial fullness & early satiety
Clonidine acts - alpha 2 sympathetic receptor agonist
& also blocks other sympathetic receptors
Evidence for acutely improving symptoms in patients
with dyspeptic symptoms & diabetic gastroparesis -
might be due to changes in accommodation
Recent study indicates that clonidine causes
hyperglycemia & also interacts with glibenclamide to ↓
hypoglycemic activity in rats
Role in improving gastric emptying remains
controversial
Current and emerging medical therapies for gastroparesis
24
25. TARGETING ACCOMMODATION
CONT’D
Other medications implicated in gastric
accommodation include acotiamide (Z-338, YM
443) - muscarinic M1/M2 receptor antagonist &
possibly an M5-like receptor approved in Japan
that enhances acetylcholine release & appears to
enhance gastric accommodation
Associated with improved dyspeptic symptoms
Current and emerging medical therapies for gastroparesis
25
26. TARGETING ACCOMMODATION
CONT’D
Buspirone -5HT1A agonist
Positive effect on gastroparesis symptomatic relief,
even without evidence showing of gastric emptying in
healthy volunteers
In addition to ↓ in transient lower esophageal
sphincter relaxation, which is major mechanism
underlying gastroesophageal reflux disorder, this
symptomatic relief might be due to fundic relaxation
& ↑ gastric accommodation
Sumatriptan - 5-HT1D/1B agonist,
Relaxes fundus & effective in functional dyspepsia
Both buspirone & sumatriptan have potential
disadvantage of slowing gastric emptying
Current and emerging medical therapies for gastroparesis
26
27. TARGETING PYLORIC
FUNCTION
Conceptually, gastric retention could be due to
impaired relaxation of pyloric sphincter, which might
be caused by a lack of normal inhibitory innervation
through nitric-oxide-producing intrinsic neurons
Nitric oxide exerts its effect through cyclic GMP as
a mediator & sildenafil which protects second
messenger from breakdown should mimic effects of
nitric oxide release & relieve gastric retention
Sildenafil did not improve emptying in pilot study of
patients with diabetic gastroparesis, possibly because
of its concurrent relaxatory action on fundus
Current and emerging medical therapies for gastroparesis
27
28. TARGETING PYLORIC
FUNCTION CONT’D
Botulinum toxin A injected into pyloric area during
endoscopy initially reported symptomatic
improvement & acceleration of gastric emptying
Two controlled trials did not demonstrate
superiority over placebo
Current and emerging medical therapies for gastroparesis
28
29. ANTIBIOTICS FOR TREATMENT
OF BACTERIAL OVERGROWTH
Gastric stasis can lead to bacterial overgrowth in
stomach & intestine
Patients with small intestinal bacterial overgrowth
also present with symptoms similar to those of
gastroparesis & various antibiotics used for
bacterial overgrowth may also improve gastric
motility
Rifaximin has gained more recent attention since it
is poorly absorbed & therefore works primarily in
intestine with fewer potential side effects
Current and emerging medical therapies for gastroparesis
29
31. SEROTONERGIC RECEPTOR
AGENTS
TD-5108 is a potent, highly selective & high-
efficacy 5-HT4 agonist
Can significantly accelerate intestinal and colonic
transit after single dosing & recent phase 2
blinded, placebo randomized control trial involving
both diabetic & idiopathic gastroparesis patients
demonstrated accelerated gastric emptying
Current and emerging medical therapies for gastroparesis
31
32. SEROTONERGIC RECEPTOR
AGENTS
CONT’D
Prucalopride - undergoing phase 3 clinical trial in
diabetic gastroparesis
Alosetron - Being considered for treatment of
gastroparesis
Naronapride - investigational 5-HT4 receptor
agonist that was designed to have similar activity
as cisapride without QT prolongation
Current and emerging medical therapies for gastroparesis
32
33. SEROTONERGIC RECEPTOR
AGENTS
CONT’D
In addition, naronapride is not metabolized by
CYP450
↑ spontaneous bowel movements in a phase 2
randomized, placebo-controlled study of patients
with chronic idiopathic constipation
Study demonstrated that it can accelerate overall
colonic transit & tends to accelerate gastric &
ascending colon emptying & loosen stool
consistency
Current and emerging medical therapies for gastroparesis
33
34. SEROTONERGIC RECEPTOR
AGENTS CONT’D
Renzapride - Gastroprokinetic agent & anti-emetic
Despite initial encouraging results, however, phase
III trial in the USA in 2008 did not show
sufficient efficacy over placebo to justify further
development
TD-2749 - selective 5-HT4 agonists - currently
being studied for use in gastroparesis
Current and emerging medical therapies for gastroparesis
34
35. MOTILIN RECEPTOR AGONISTS
Several erythromycin derivatives are being studied
as promotilides without antibiotic activity
EM574 has emerging evidence to improve delayed
gastric emptying in dogs, but evidence in humans is
still lacking
Various other coded molecules in pipeline are
ABT81229, KC11458, GM611 , GSK962040
Current and emerging medical therapies for gastroparesis
35
36. OTHER CCK-A ANTAGONIST
Loxiglumide ↑ gastric & colonic motilities & reduces
visceral perception
Appears effective for constipation & studies in
healthy volunteers showed acceleration of both
liquid & solid gastric emptying
Current and emerging medical therapies for gastroparesis
36
37. GHRELIN AND GHRELIN
RECEPTOR AGONISTS
Pharmacological doses of ghrelin accelerate gastric
emptying & improve symptoms but contraction of
proximal stomach may conceivably aggravate post-
prandial symptoms
TZP-101 - small studies to ↓ overall post-meal
symptom intensity & post-prandial fullness &
improve symptoms in six patients with severe
gastroparesis
Other coded compounds undergoing trials are TZP
-102, RM -131
Current and emerging medical therapies for gastroparesis
37
38. GUANYL CYCLASE AGONIST
Linaclotide - peptide agonist of guanylate cyclase
2C - ↑ smooth muscle contraction and promotes
bowel movement
Target receptor is less expressed in stomach,
some have used this off-label for gastroparesis
IW-9179 - GC-C agonist - for potential treatment
of functional dyspepsia and gastroparesis
Current and emerging medical therapies for gastroparesis
38
39. OTHER PROMOTILITY
MEDIATORS
Calcitonin gene-related peptide, or CGRP - potent
smooth muscle relaxant shown to slow gastric
emptying in healthy rodents
CGRP & transient receptor potential vanilloid
subtype 1 (TRPV1) antagonists - potential in
treatment of gastroparesis
Recent study TRPV1 blockade elicited marked, but
reversible & generally plasma concentration
dependent hyperthermia
Current and emerging medical therapies for gastroparesis
39
40. OTHER PROMOTILITY
MEDIATORS CONT’D
Lubiprostone
selective type 2 chloride channel (ClC-2) activator
- induces intestinal secretion & has been shown to
relieve constipation in clinical trials
Some of its action may be mediated through
prostaglandin E2 effects, raising possibility that
this could also enhance gastric emptying
Accelerated small bowel & colonic transit & fasting
↑ gastric volume but retarded gastric emptying
↓ fullness 30 min after fully satiating meal
Current and emerging medical therapies for gastroparesis
40
41. CONCLUSION
Current available medications are limited symptomatic
control is aimed at improving gastric emptying , alleviating
nausea and vomiting, and treating abdominal pain . Many
drugs are in pipeline for treating gastroparesis.
Various newer mechanism under study are
1. Serotonergic agents – prucalopride
2. Motilin receptor agonists – EM574
3. CCK – A Antagonist- loxiglumide
4. Ghrelin receptor antagonists – TZP101
5. Guanyl cyclase agonist – Linactolide
6. Calcitonin gene related peptides antagonists
Current and emerging medical therapies for gastroparesis
41
42. REFERENCES
Current and Emerging Medical Therapies for
Gastroparesis ,Xiaofeng Zhao, PhDHiroshi
Mashimo, Drugs 2015
“ The pharmacological basis of therapeutics”
Goodman and Gilman( 12th edition )
Basic and clinical pharmacology – Bertram Katzung
(12th edition)
Current and emerging medical therapies for gastroparesis
42
44. REMOVE ???
A number of herbal preparations have emerged as
dietary supplements for treatment of functional
bowel and gastroparesis symptoms
STW5 (Iberogast, Steigerwald Arzneimittelwerk
GmbH) is a herbal preparation of nine herbs
(clown’s mustard, German chamomile, angelica,
caraway, milk thistle, lemon balm, peppermint,
celandine & licorice)
Initial studies of Iberogast - show promise in
treatment of dyspeptic symptoms & for
gastroparesis, although gastric emptying was not
enhanced
Current and emerging medical therapies for gastroparesis
44
45. CHOLECYSTOKININ (CCK)
ANTAGONISTS
Cholecystokinin (CCK) natural hormone in body that
influences gastric motor, gall bladder & pancreatic
enzyme function
Current and emerging medical therapies for gastroparesis
45
46. TZP-102 - oral counterpart of TZP-101
Did not accelerate gastric emptying
Initially ↓ composite symptom score of nausea, inability to
finish meals, upper abdominal pain & bloating
Phase 2b trial with diabetic gastroparesis - no significant
symptomatic benefit over placebo
RM-131 - pentapeptide synthetic ghrelin receptor agonist
In animal models has nearly 100-fold greater potency than
native ghrelin and a longer plasma half-life.
Two studies - accelerated gastric emptying & ↓ subjective
vomiting severity but not other GI symptoms
Current and emerging medical therapies for gastroparesis
46
& are generally more common with long-term and high-dose use
Domperidone - cause hyperprolactinemia.
Antihistamines
Diphenhydramine, promethazine & meclizine - commonly prescribed anti-histamines used as anti-emetics
Dimenhydrinate can improve tachygastria occurring in motion sickness has been associated with
prolongation of QT interval, which can lead to the potentially fatal heart rhythm known as torsades de pointes.
Off-label use of low-dose tricyclic anti-depressant (TCA) drugs
One of mainstays for treating chronic abdominal pain and in clinical practice
Used to treat gastroparesis
Shown to be safe in phase I trials (Europe & Japan) & in phase II trial conducted in patients with functional dyspepsia (USA & Europe)
Among antibiotics used for small intestinal bacterial overgrowth,
MKC-733 has been found to delay liquid gastric emptying in association with relaxation of the proximal stomach, to stimulate fasting antroduodenal migrating motor complex activity, and to accelerate small intestinal transit. Studies are underway to assess its role in gastroparesis.
ABT81229 - ↑ rate of gastric emptying but did not show symptom relief, such as nausea &bloating, compared to placebo
KC11458 - accelerates gastric emptying in animals & healthy humans but fails to accelerate gastric emptying in diabetic gastroparesis
GM611 enhances gastric emptying & post-prandial glycemic control but showed no improvement in phase 2 studies of diabetic patients, although paradoxically, patients with non-delayed gastric emptying showed improved response rates over those with delayed gastric emptying
GSK962040 non motilide motilin receptor agonist with low molecular mass that selectively activates motilin receptor
Phase 1 clinical trials - improves gastric empting in diabetic gastroparesis
Preliminary results of a phase II clinical trial showed significant symptom improvement above placebo after 28 days of therapy without evidence for tachyphylaxis
TRPV1-selective antagonists like AMG 517 cannot be used systemically by itself.
One study using scintigraphic GI & colonic transit, single-photon emission computed tomography (SPECT) to measure gastric volumes, and the nutrient drink (Bsatiation^) test to measure maximal tolerated volumes and post-prandial symptoms showed that
and await further results from the phase 2 studies.